Drug Discovery World

AUGUST 11, 2023

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM’s CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation.

Reagent 52

Reagent Development Gene Editing Production 52

pharmaphorum

DECEMBER 16, 2022

Clinical trials technology company Saama has hired Dr Clinton White as its new chief delivery officer. Drawing on 25 years in clinical research, White will oversee Saama’s project delivery teams. Pharmaceutical supplier PBSC has tapped Jose Ruiz as the new president and general manager for its US office.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

XTalks

AUGUST 18, 2020

The study was funded by a clinical research agreement with the NBA and the players’ union – the National Basketball Players Association (NDG) – which together, contributed over $500,000 to fund the Yale study. The results of the two tests displayed almost universal equivalency.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

.” With the panel’s authorization, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or reagent availability. Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY ® System.

Genetic Analysis 52

Genetic Analysis Genome Genomics Reagent 52

Roots Analysis

AUGUST 28, 2022

Currently, several stakeholders are engaged in offering integrated solutions (platforms, software applications, services) to perform tissue analysis and spatial phenotyping, across the full continuum from discovery through translational and clinical research.

Genome 52

Genome Genomics RNA Genome Project 52

The Pharma Data

DECEMBER 23, 2020

The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences.

Drugs 52

Drugs Licensing Licensing Vaccination 52